The modern supply chain is facing immense challenges such as increasing customer demands, disruptive technologies and global uncertainty. Companies need to transform their supply chains into robust, data-driven networks in order to remain competitive.

The Covid-19 pandemic has not only exposed weaknesses in the pharmaceutical industry's global supply chain, but has also initiated a transformation. Contract Development and Manufacturing Organizations (CDMOs) in particular are faced with the task of redefining their role and creating long-term value through strategic partnerships, digitalization and sustainable innovation.

The generics and biosimilars industry is undergoing fundamental change. Technological innovations, increasing regulatory requirements and the influence of platform companies such as Amazon Pharmacy are creating new challenges and opportunities. This article shows how the industry could develop by 2030+ and which scenarios will shape manufacturers in the future.

Digitalization is transforming the pharmaceutical industry with technologies such as AI, automation and big data. It increases efficiency and transparency and creates competitive advantages.

The audit trail is firmly anchored in regulatory requirements and guidelines, but the practical implementation is not always immediately comprehensible. This article shows how the requirements for the audit trail can be specified in the user requirements.

Every company must protect itself against cyber attacks. Especially in the GMP environment, there are special challenges to overcome.